Efficacy and safety of cyberknife in the treatment of elderly patients with early stage non-small cell lung cancer
10.3969/j.issn.1673-9701.2024.05.012
- VernacularTitle:射波刀治疗老年早期非小细胞肺癌的治疗效果与安全性
- Author:
Xue LI
1
,
2
;
Yanming WANG
3
;
Qin TIAN
4
;
Hongwang ZHANG
1
,
2
Author Information
1. Postgraduate Training Base of 960th Hospital of PLA, Jinzhou Medical University, Jinzhou 121012, Liaoning, China
2. Department of Radiation Oncology, 960th Hospital of PLA, Jinan 250031, Shandong, China
3. Department of Radiation Oncology, 960th Hospital of PLA, Jinan 250031, Shandong, China
4. Department of Radiation Oncology, Shandong Provincial Third Hospital, Jinan 250031, Shandong, China
- Publication Type:Journal Article
- Keywords:
Elderly patients;
Non-small cell lung cancer;
Early stage lung cancer;
Stereotactic body radiotherapy;
Cyberknife
- From:
China Modern Doctor
2024;62(5):51-56
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of Cyberknife in the treatment of elderly patients(aged≥75 years)with early stage non-small cell lung cancer(NSCLC),and to compare the results with those of patients aged<75 years.Methods We retrospectively analyzed 75 patients with early(T1-2N0M0)NSCLC admitted to the 960th Hospital of Jinan People's Liberation Army from January 2013 to October 2019.There were 32(42.7%)patients aged<75 years,and 43(57.3%)patients aged≥75 years.All patients were treated with 45-66Gy/3-8F,60%-85%isodose line as the prescription dose to cover planning target volume(PTV),and irradiation once a day and five times a week.The clinical efficacy,survival status and radiotherapy toxicity of the two groups were compared,and the factors affecting the efficacy of elderly patients were analyzed.Results The disease control rates of patients aged<75 and≥75 years were 96.9%and 93.0%,respectively(P>0.05).The 5-year local control rate(LC),progression-free survival(PFS)and cancer-specific survival(CSS)were 70.9%and 85.4%,58.5%and 54.4%,and 70.4%and 64.5%,respectively(P>0.05).However,the overall survival(OS)of patients aged≥75 years was significantly lower than that of patients aged<75 years,and the 5-year OS was 49.2%and 68.2%,respectively(P<0.05).There was no significant difference in the treatment complications between the two groups(P>0.05).Multivariate analysis showed that biologic effective dose(BED)was an independent factor affecting OS in patients aged≥75 years.Conclusion Stereotactic body radiotherapy with cyberknife is a safe and effective treatment for elderly patients with early stage NSCLC who are not suitable for surgery.
